News

Healio21h
Mepolizumab lowers severe exacerbation risk in COPD, type 2 inflammation at 104 weeks
Patients with COPD and type 2 inflammation receiving mepolizumab vs. placebo had decreased moderate and severe exacerbation ...
The American Journal of Managed Care1d
FDA Approves Mepolizumab as First Once-Monthly Biologic for COPD With Eosinophilic Phenotype
FDA approves mepolizumab (Nucala; GSK) as the first monthly biologic for chronic obstructive pulmonary disease (COPD), significantly reducing exacerbations in patients with an eosinophilic phenotype.
Medscape3d
COPD Diagnosis Reboot Identifies More At-Risk Individuals
We have developed a new, multidimensional diagnostic schema for COPD that incorporates spirometry, symptoms, and imaging and ...
MedPage Today on MSN6d
Adding CT, Symptoms Improves COPD Diagnosis
The schema newly classified 15.4% of persons without airflow obstruction as having COPD by minor diagnostic category, Surya P ...
Pulmonology Advisor3d
Women and Lung Disease: Sex-Specific Patterns in COPD, Asthma, and OSA
Women with COPD, asthma, and OSA may go undiagnosed or without proper care because their symptomatology differs from the male ...
Medscape4d
Are Your Patients With COPD Inhaling Eucalyptus Oil? Know the Risks
Eucalyptus oil was first used by Aboriginal Australians, who crushed the leaves for their antiseptic properties or steamed ...